ArticleGenetics in medicine : official journal of the American College of Medical Genetics2010
Myriad Genetics: In the eye of the policy storm.
Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 112 citations in OpenAlex.
- Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.Journal of oncology practice · 2016Trial
- Inverting the model of genomics data sharing with the NHGRI Genomic Data Science Analysis, Visualization, and Informatics Lab-space.Cell genomics · 2022Article
- The fall of the innovation empire and its possible rise through open science.Research policy · 2021Article
- Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese Press.Asian bioethics review · 2020Article
- Alienation from the Objectives of the Patent System: How to Remedy the Situation of Biotechnology Patent.Science and engineering ethics · 2019Article
- The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project.Journal of the history of biology · 2018Article
- Corporate control and global governance of marine genetic resources.Science advances · 2018Article
- Gene patents still alive and kicking: their impact on provision of genetic testing for long QT syndrome in the Canadian public health-care system.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Sharing Data to Build a Medical Information Commons: From Bermuda to the Global Alliance.Annual review of genomics and human genetics · 2017Review
- Conflicts of interest in genetic counseling: acknowledging and accepting.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.Psycho-oncology · 2015Article
- Baseball bats and chocolate chip cookies: the judicial treatment of DNA in the myriad genetics litigation.Cold Spring Harbor perspectives in medicine · 2014Review
- Patentability of genes: a European Union perspective.Cold Spring Harbor perspectives in medicine · 2014Review
- Phase changes in the BRCA policy domain.Journal of religion and health · 2014Review
- Variants of uncertain significance in BRCA: a harbinger of ethical and policy issues to come?Genome medicine · 2014Article
- After Myriad: Genetic Testing in the Wake of Recent Supreme Court Decisions about Gene Patents.Current genetic medicine reports · 2014Review
- Transparency tools in gene patenting for informing policy and practice.Nature biotechnology · 2013Article
- Gene patents: a broken incentives system.Journal of religion and health · 2013Review
- Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Genetics. Moving beyond "isolated" gene patents.Science (New York, N.Y.) · 2013Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
From the late 1980s, a storm surrounding the wisdom, ethics, and economics of human gene patents has been brewing. The various winds of concern in this storm touched on the impact of gene patents on basic and clinical research, on health care delivery, and on the ability of public health care systems to provide equal access when faced with costly patented genetic diagnostic tests. Myriad Genetics, Inc., along with its subsidiary, Myriad Genetic Laboratories, Inc., a small Utah-based biotechnology company, found itself unwittingly in the eye of this storm after a series of decisions it made regarding the commercialization of a hereditary breast cancer diagnostic test. This case study examine the background to Myriad's decisions, the context in which these decisions were made and the policy, research and business response to them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.